Risk classification The Dutch Federation of University Medical Centers (in Dutch: 'Nederlandse Federatie van Universitair Medische Centra') proposed a guideline for determination of the risk classification of a clinical trial. As stated above, the study medication and examinations/test are generally considered to be safe, with a small increased risk for hypoglycemia. For the latter, appropriate measures will be taken to minimize risk. Within the T2DM population, our study population can be considered as relatively low risk. However, sporadic serious side effects have been described (dehydration, hypovolemia, severe hypoglycemia), although most patients recover quickly. Therefore, while there is a low risk, the possible consequences might be 'moderate' to 'serious'. Therefore, the investigators feel that the current study has a classification of 'moderate risk'.